Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.39 |
| ▸ | ABL1 | P00519 | 7/20 | 0.38 |
| ▸ | GRM5 | P41594 | 3/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415556 | 1.00 | PRMT5 (0.40) | PRMT5WDR77CYP11B1CYP11B2ABL1 | |
| SCHEMBL314358 | 0.88 | CYP11B2 (0.38) | CYP11B1CYP11B2ABL1GRM5SLC22A12 | |
| SCHEMBL314359 | 0.88 | CYP11B2 (0.38) | CYP11B1CYP11B2ABL1GRM5SLC22A12 | |
| SCHEMBL2412631 | 0.87 | RPS6KA3 (0.40) | CYP11B2ABL1RPS6KA3SLC22A12CYP1A2 | |
| SCHEMBL2412635 | 0.87 | RPS6KA3 (0.40) | CYP11B2ABL1RPS6KA3SLC22A12CYP1A2 | |
| SCHEMBL2410312 | 0.85 | GRM5 (0.37) | ABL1GRM5RPS6KA3SLC22A12 | |
| SCHEMBL2410309 | 0.85 | GRM5 (0.37) | ABL1GRM5RPS6KA3SLC22A12 | |
| SCHEMBL2414587 | 0.83 | MKNK1 (0.38) | PRMT5WDR77CYP11B1CYP11B2ABL1 | |
| SCHEMBL2414591 | 0.83 | MKNK1 (0.38) | PRMT5WDR77CYP11B1CYP11B2ABL1 | |
| SCHEMBL2408725 | 0.83 | MGLL (0.37) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013010-B2 | 5-thioxylopyranose compounds | LABORATOIRES FOURNIER S.A. (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | LABORATOIRES FOURNIER S.A (FR) | 2009-07-23 | — | — | US | disclosed |
| EP-2066681-A1 | NEW DERIVATIVES OF 5-THIOXILOPYRANOSE | LABORATOIRES FOURNIER SA (FR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008037923-A1 | NEW DERIVATIVES OF 5-THIOXILOPYRANOSE | LABORATOIRES FOURNIER S.A. (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | TPMT, PNPO, CYP3A5 | PRMT5 961/4885WDR77 3751/4885CYP11B1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.